1
|
DeRidder A, Mainor C, Goloubeva O, Ioffe O, Bellavance E, Tkaczuk K, Rosenblatt P. Abstract P5-13-02: Chemoprevention utilization in patients with a history of atypical hyperplasia, atypical lobular hyperplasia, or lobular carcinoma in-situ: A retrospective chart review of patients diagnosed at an urban hospital with a large minority patient population. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The Breast Cancer Prevention Trial (BCPT) and the Study of Tamoxifen and Raloxifene (STAR) trial showed that chemoprevention can reduce the risk of invasive breast cancer by nearly 50%. Despite these results, studies have shown that while an estimated 2 million women in the United States are eligible for chemoprevention, actual acceptance of these medications is low. Improving chemoprevention utilization rates hinges on better understanding current rates of utilization and factors affecting patient acceptance. Reported rates and barriers to chemoprevention use may not accurately reflect true utilization patterns in lower socioeconomic, minority patient populations. The aim of this IRB approved retrospective study was to characterize the rate and factors associated with chemoprevention use in patients with a diagnosis of atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), or lobular carcinoma in-situ (LCIS) at an urban hospital with a high minority population.
Methods – A retrospective chart review was performed for all diagnoses of ADH, ALH, and LCIS made at the University of Maryland Medical Center between the years 2005-2015. Concurrent DCIS or invasive cancer were excluded. Demographic and clinical information including age, race, education, GAIL score, BMI, and use of chemoprevention was recorded. Univariable and multivariable logistic regression were performed to identify factors associated with chemoprevention discussion and use.
Results – 301 diagnoses of ADH/ALH/or LCIS were obtained and 127 women were eligible for analysis. The median age was 53 years old with 47% of patients being premenopausal. The majority were African-American (65%) and 51% had a high school degree or less. The median 5 year risk for developing breast cancer based on the GAIL model was 2.4%. The chemoprevention utilization rate for our patient population was 28% (n=34). Race, menopausal status, and breast density were not associated with chemoprevention discussion or use. We found that patients were more likely to have a chemoprevention discussion with their provider if they were older (p=0.03) or if they were referred to medical oncology (p<0.001, Fisher's exact test).
Conclusions - Our study evaluated chemoprevention use in an understudied predominantly African-American patient population. We found a higher rate of chemoprevention utilization (28%) compared to previously reported rates. Age and medical oncology referral had a significant impact on provider-patient chemoprevention discussion. Though limited due to small sample size, our study nonetheless provided thought provoking results. Older patients may be at higher risk for developing breast cancer, however, it is important to consider that younger patients with risk factors may have a more favorable endocrine therapy benefit-risk ratio. In addition, our results highlight the importance of encouraging all physicians who are involved in women's' breast health to have a chemoprevention discussion with eligible patients, or for these physicians to refer patients to a medical oncologist for further discussion.
Citation Format: DeRidder A, Mainor C, Goloubeva O, Ioffe O, Bellavance E, Tkaczuk K, Rosenblatt P. Chemoprevention utilization in patients with a history of atypical hyperplasia, atypical lobular hyperplasia, or lobular carcinoma in-situ: A retrospective chart review of patients diagnosed at an urban hospital with a large minority patient population [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-13-02.
Collapse
Affiliation(s)
- A DeRidder
- University of Maryland Medical Center, Baltimore, MD
| | - C Mainor
- University of Maryland Medical Center, Baltimore, MD
| | - O Goloubeva
- University of Maryland Medical Center, Baltimore, MD
| | - O Ioffe
- University of Maryland Medical Center, Baltimore, MD
| | - E Bellavance
- University of Maryland Medical Center, Baltimore, MD
| | - K Tkaczuk
- University of Maryland Medical Center, Baltimore, MD
| | - P Rosenblatt
- University of Maryland Medical Center, Baltimore, MD
| |
Collapse
|
2
|
Serrero G, Hawkins D, Hicks D, Rosenblatt P, Tait N, Yue B, Tkaczuk K. Abstract P2-02-10: Circulating level of GP88/Progranulin is associated with clinical outcome and overall survival in stage 4 breast cancer patients. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-02-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Monitoring of disease status in metastatic breast cancer (MBC) patients is a necessary step for an optimal management of patients during and post-therapy. Imaging technologies are the methods of choice in the standard of care to monitor therapy response and disease status in MBC patients. These methods are expensive, time-consuming and have limited sensitivity for real time monitoring. Measurements of circulating tumor markers CA15-3, CA125 and CEA have contributed, albeit with limitation, minimally invasive methods for MBC disease management. It is our hypothesis that measuring biomarkers involved in tumor biological processes may provide better evaluation of the disease state and thus aid real-time clinical management of MBC patients. Thus, addition of such new circulating disease biomarkers may improve the management of MBC patients. The 88kDa glycoprotein Progranulin (GP88/PGRN) fit these criteria. GP88/PGRN is expressed in tumor tissue and not in normal mammary tissue counterpart and secreted in the circulation of BC patients. Biological studies have established GP88/PGRN as a critical driver of BC cell proliferation, survival, invasiveness and drug resistance. Clinical studies have demonstrated that high tumor GP88/PGRN expression was prognostic for recurrence and that breast cancer patients had a statistically elevated GP88/PGRN serum level compared to healthy individuals. In the present study, we examined whether GP88/PGRN serum levels were elevated in MBC patients and whether GP88/PGRN circulating levels were correlated with patient clinical outcome and overall survival.
Under an IRB approved protocol at the University of Maryland Greenebaum Comprehensive Cancer Center, 101 stage 4 BC patients undergoing standard of care therapy and meeting the inclusion criteria were consented and enrolled. MBC patients' demographics, clinical and disease characteristics and therapies were collected as part of the study. Blood samples were collected from each patient at specific times at follow-up visits during and post-therapy. The prepared serum was stored at -80C until tested for GP88 using a GP88 enzyme linked immunoassay developed in our laboratory.
Statistical analysis using Kaplan-Meier functions established whether there was a correlation between GP88/PGRN serum level and overall survival in MBC patients. MBC patients with distinct survival characteristics (P=0.0002) could be stratified based on their circulating GP88/PGRN levels. Analysis of this association was carried out in MBC patients based on their age, race, tumor characteristics, receptor status and metastatic burden (number and sites of metastasis) and will be reported. We conclude that circulating levels of GP88/PGRN in MBC patients are correlated with overall survival and that monitoring circulating GP88/PGRN levels would provide additional information and valuable insight into real-time MBC disease status.
This work was supported by grant R43 CA 210817-01A1 to GS.
Citation Format: Serrero G, Hawkins D, Hicks D, Rosenblatt P, Tait N, Yue B, Tkaczuk K. Circulating level of GP88/Progranulin is associated with clinical outcome and overall survival in stage 4 breast cancer patients [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-02-10.
Collapse
Affiliation(s)
- G Serrero
- A&G Pharmaceutical Inc., Columbia, MD; University of Minnesota, Minneapolis, MN; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
| | - D Hawkins
- A&G Pharmaceutical Inc., Columbia, MD; University of Minnesota, Minneapolis, MN; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
| | - D Hicks
- A&G Pharmaceutical Inc., Columbia, MD; University of Minnesota, Minneapolis, MN; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
| | - P Rosenblatt
- A&G Pharmaceutical Inc., Columbia, MD; University of Minnesota, Minneapolis, MN; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
| | - N Tait
- A&G Pharmaceutical Inc., Columbia, MD; University of Minnesota, Minneapolis, MN; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
| | - B Yue
- A&G Pharmaceutical Inc., Columbia, MD; University of Minnesota, Minneapolis, MN; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
| | - K Tkaczuk
- A&G Pharmaceutical Inc., Columbia, MD; University of Minnesota, Minneapolis, MN; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
| |
Collapse
|
3
|
Diwanji T, Lin J, Lozano A, Chhabra A, Molitoris J, Hanlon A, Snider J, Cohen R, Cheston S, Citron W, Nichols E, Tkaczuk K, Rosenblatt P, Bellavance E, Kesmodel S, Feigenberg S. Impact of Chemotherapy on Acute Toxicity in Breast Cancer Patients Treated with Breast Conserving Surgery and Hypofractionated Whole Breast Irradiation: A Single Institution Experience. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Chhabra A, Molitoris J, Diwanji T, Snider J, Bentzen S, Tkaczuk K, Rosenblatt P, Kesmodel S, Bellavance E, Nichols E, Feigenberg S. Lack of Consensus Guideline Driven Approach for Utilization of Accelerated Partial Breast Irradiation in the ASTRO “Cautionary” Group: A National Cancer Database Analysis. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Kowalski E, Cohen J, Snider J, Molitoris J, Nichols E, Chen W, Bellavance E, Kesmodel S, Tkaczuk K, Rosenblatt P, Feigenberg S. Positron Emission Tomography/Computed Tomography (PET/CT) in the Initial Evaluation of Women with Nonmetastatic Breast Cancer Can Frequently Alter Management. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Feigenberg S, Bentzen S, Milburn M, Snider J, Kesmodel S, Bellavance E, Cohen R, Becker S, Mutaf Y, Tkaczuk K, Rosenblatt P, Nichols E, Niu Y, Yu C. The Initial Clinical Experience of a Novel Breast Specific Stereotactic Radiosurgery Device. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.624] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Rice S, Molitoris J, Bentzen S, Tkaczuk K, Rosenblatt P, Kesmodel S, Bellavance E, Nichols E, Feigenberg S. Trends in Utilization of Hypofractionated Whole Breast Irradiation in Triple Negative Breast Cancer: A National Cancer Database Analysis. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Diwanji T, Molitoris J, Chhabra A, Bentzen S, Tkaczuk K, Rosenblatt P, Kesmodel S, Bellavance E, Cohen R, Nichols E, Feigenberg S. Utilization of Hypofractionated Whole Breast Radiation Therapy in Patients Receiving Chemotherapy (2004-2013): A National Cancer Database Analysis. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Iyer L, Faramand R, Jung S, Rosenblatt P, Campassi C, Dromi S, Dorgan J, Tkaczuk K. Abstract P3-02-08: Association of background parenchymal enhancement with breast cancer risk factors and tumor characteristics. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-02-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Background Parenchymal Enhancement (BPE) in a dynamic contrast enhanced (DCE)MRI refers to change in morphology and temporal degree of enhancement expressing physiology of breast tissue. Improvements in the analysis and interpretation of BPE have been shown to increase diagnostic accuracy of the MRI. We explored associations of BPE with breast cancer(BC) risk factors and tumor characteristics.
Methods: We conducted a retrospective chart review study of 149 women who were treated for BC at the University of Maryland Medical Center(UMMC) between 2003-2015. Institutional Review Board approval was obtained. Subjects had BI-RADS 4,5 or 6 on their mammograms and/or biopsy proven BC. Women with false positive mammograms (n=2), missing BPE grade in their MRI reports (n=6), metastatic BC at diagnosis (n=2), MRIs done outside of a year of diagnosis (n=3), and who followed up outside UMMC (n=1) were excluded. Final analysis included 135 women. We used 1.5T or 3T scanners for DCE MRI. Standard contrast enhanced MRI protocol, T1, T2, and dynamic series were acquired according to American College of Radiology requirements for breast MRI accreditation and interpreted with Maximum Intensity Projection and subtracted imaging. Fellowship-trained breast imagers performed qualitative BPE assessment as per standard BI-RADS classification. BI-RADS classes were grouped as high BPE (BI-RADS moderate and marked) and low BPE (BI-RADS minimal and mild). Multivariable logistic regression was used to assess associations with predictors including individual and tumor characteristics.
Results: Preliminary analyses showed BPE was significantly associated with alcohol intake, with drinkers being more likely to have high BPE compared to non-drinkers [odds ratio (OR) =3.08 (95% confidence interval (CI) = 1.34-7.09; p=0.008]. Women who received adjuvant radiation for their BC were less likely to have high BPE compared to women who did not undergo radiation [OR= 0.37 (95% CI=0.15-0.90); p=0.03] implying higher likelihood of breast conservation surgery in the former group. High BPE was less often observed for invasive ductal carcinoma histology vs. in-situ ductal carcinomas [OR= 0.40 95% CI=0.16-1.00); p=0.05] and in post- vs. premenopausal women [OR=0.47 (95%CI=0.22-1.00); p=0.05]. No association was found between BPE and race, BMI, prior HRT/OCP use, smoking, or ER/PR/HER-2 status.
Conclusion: We observed association between higher BPE and alcohol exposure and lower BPE and, invasive ductal histology, postmenopausal status at diagnosis of BC and adjuvant radiation for BC. Larger studies are needed to corroborate our findings and identify the underlying mechanisms.
Citation Format: Iyer L, Faramand R, Jung S, Rosenblatt P, Campassi C, Dromi S, Dorgan J, Tkaczuk K. Association of background parenchymal enhancement with breast cancer risk factors and tumor characteristics [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-02-08.
Collapse
Affiliation(s)
- L Iyer
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD
| | - R Faramand
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD
| | - S Jung
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD
| | - P Rosenblatt
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD
| | - C Campassi
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD
| | - S Dromi
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD
| | - J Dorgan
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD
| | - K Tkaczuk
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD
| |
Collapse
|
10
|
Tang SC, Kumthekar P, Brenner A, Kesari S, Piccioni D, Anders C, Carillo J, Chalasani P, Kabos P, Puhalla S, Garcia A, Tkaczuk K, Ahluwalia M, Lakhani N, Ibrahim N. ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.02] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Lin J, Bluebond-Langner R, Choi E, Cheston S, Nichols E, Cohen R, Bentzen S, Drogula C, Kesmodel S, Bellavance E, Rosenblatt P, Tkaczuk K, Slezak S, Feigenberg S. Radiation Lumpectomy Boost and Acute Treatment Toxicities in Patients With or Without Reduction Mammoplasty as Part of Breast Conserving Treatment. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Horton J, Baker J, Blitzblau R, Georgiade G, Hwang E, Duffy E, Morgan M, Feigenberg S, Citron W, Kesmodel S, Bellavance E, Drogula C, Tkaczuk K, Galandak J, Nichols E. Preoperative Partial Breast Radiation Therapy: Short-term Imaging Outcomes With Two Unique Treatment Regimens. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Katz D, Patel K, Nichols E, Rosenblatt P, Tkaczuk K, Baron K, Heiss B, Marshall J, Tait N, Gottlieb S, Feigenberg S. The Use of Radiation Therapy Does Not Appear to Have an Impact on the Incidence of Heart Failure in Patients Receiving Targeted HER2 Based Systemic Therapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Chumsri S, Tait N, Shetty J, Lewis J, Medeiros M, Bao T, Goloubeva O, Singh H, Sivasailam S, Sabnis G, Kazi A, Mann D, Kesmodel S, Brodie A, Tkaczuk K. Abstract OT3-2-11: A phase II study of letrozole and lapatinib followed by an addition of everolimus in postmenopausal women with advanced endocrine resistant breast cancer (BC). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot3-2-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Several preclinical studies demonstrated that crosstalk between growth factor receptor pathways, particularly HER2, and ER signaling confers resistance to endocrine therapy (ET). There are emerging data showing the involvement of immune system and miRNA with endocrine resistance. EGF30008 trial showed a benefit of lapatinib in combination with letrozole, mainly in HER2-positive (HER+) metastatic BC (MBC) while a subset analysis of this trial showed that HER2-negative (HER2-) patients (pts) with acquired endocrine resistance may also benefit from this combination. Our preclinical study suggests that everolimus is synergistic with letrozole and lapatinib.
Trial Design: This is a single arm phase II study for postmenopausal women with hormone receptor-positive MBC progressing after aromatase inhibitor, tamoxifen, or fulvestrant. The total target accrual is 76 pts (38 HER2+ pts and 38 HER- pts). In the first phase of the study, pts will be treated with letrozole and lapatinib (1,500 mg daily). Upon disease progression, pts will enter the second phase where everolimus (5 mg daily) will be added to letrozole and the dose of lapatinib will be reduced to 1,250 mg daily. For correlative studies, peripheral blood samples will be serially collected to evaluate for serum HER2 extracellular domain (ECD), circulating miRNAs, PC cell-derived growth factor (GP88), immune regulatory cells including myeloid-derived suppressor cells, NK cells, and Treg cells. These parameters will be correlated with tumor response. In pts with accessible tumors, optional serial biopsies will be performed at baseline and upon progression in each phase of the study. The tumor tissue will be tested for total HER1, HER2, and HER2 expressions as well as HER2:HER2 homodimers, HER2:HER3 heterodimers, HER1:HER2 heterodimers, p95, and HER3/PI3K (p85 subunit) using VeraTag assay.
Statistical Method: The primary objective is to evaluate the clinical benefit rate (CBR: CR, PR, SD > 24 weeks) of the combination of letrozole and lapatinib as well as the combination of everolimus, letrozole, and lapatinib. This is a three-stage design which is an extension of the Simon's two-stage design. The sample size is based on the assumption that a CBR below 10% (null hypothesis) would indicate ineffective therapy and the statistical power is set at a higher CBR of 30% which we consider is plausible. Therefore, if 0 of the first 10 pts in each cohort have clinical benefit, the study will be closed; otherwise additional 8 pts will be enrolled. If ≤ 1 of the total 18 pts has clinical benefit, the study will be closed; otherwise an additional 9 pts will be enrolled. If ≤ 5 pts have clinical benefit the therapy is considered not promising; and if ≥ 6 pts of the total of 27 have clinical benefit, the therapy is considered worth pursuing. This design has ∼90% probability to accept the therapy for further trials if the true CBR is indeed at least 30% and 10% probability to accept it if the true clinical benefit is indeed below 10%.
To date, there are a total of 6 pts enrolled. Accrual is currently ongoing. Please contact ntait@umm.edu for further information.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT3-2-11.
Collapse
Affiliation(s)
- S Chumsri
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - N Tait
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - J Shetty
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - J Lewis
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - M Medeiros
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - T Bao
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - O Goloubeva
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - H Singh
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - S Sivasailam
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - G Sabnis
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - A Kazi
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - D Mann
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - S Kesmodel
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - A Brodie
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| | - K Tkaczuk
- University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD
| |
Collapse
|
15
|
Feigenberg S, Staats P, Citron W, Drogula C, Cohen R, Kesmodel S, Bellavance E, Chumsri S, Tkaczuk K, Regine W. Near 25% Complete Pathologic Response Following Preoperative Accelerated Partial Breast Radiation Therapy (APBI) Using 3-dimensional Conformal Radiation Therapy (3D CRT). Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Awan M, Bellavance E, Kesmodel S, Ioffe O, Campassi C, Tkaczuk K, Chumsri S, Bao T, Feigenberg S. Can Breast MRI Select Patients for Treatment With Preoperative APBI? Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Feigenberg S, Christenson E, Staats P, Webb T, Chumsri S, Tkaczuk K, Nichols E, Kesmodel S, Bellavance E, Regine W. Preoperative Accelerated Partial Breast Radiation Is Associated With Decreased Cd8+ Cells in Patients With Early Breast Cancer. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
Bao T, Tarpinian K, Medeiros M, Gould J, Jeter S, Cai L, Tait N, Shetty J, Lewis J, Gitten L, Betts K, Hoffman A, Feigenberg S, Chumsri S, Armstronge DK, Bardia A, Tan M, Stebbing J, Folkerd E, Dowsett M, Singh H, Tkaczuk K, Stearns V. P4-12-13: A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors: First Interim Analysis. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-12-13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Aromatase inhibitors (AIs) are recommended as first-line adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive breast cancer, as monotherapy or sequential therapy after tamoxifen. AI-associated musculoskeletal symptoms (AIMSS) occur in approximately 50% of women receiving AIs and in some may result in discontinuation of treatment. Symptom management is essential to ensure that breast cancer patients receive the full recommended duration of AI therapy. We conducted a randomized, placebo-controlled trial to evaluate the effect of acupuncture on AIMSS and report the first interim analysis.
Method: Postmenopausal women with early stage breast cancer, experiencing AIMSS, who had not had acupuncture in the year prior to the study, were eligible. Patients were randomized to 8 weekly acupuncture or sham acupuncture. Health assessment questionnaire disability index (HAQ-DI ranging 0–3.0) and pain visual analog scale (VAS ranging 0–100) were used to assess clinical musculoskeletal disorder severity at weeks 0, 4, 8, and 12 or 24. Change in HAQ-DI (ΔHAQ-DI) and VAS scores (ΔVAS) from baseline were compared between patients receiving acupuncture versus sham acupuncture using exact Wilcoxon rank sum test. Serum samples were collected for measurements of estrogens and beta endorphin concentrations and cytokine profile before and after the intervention to evaluate the etiology of AIMSS and the mechanism of acupuncture in treating AIMSS.
Results: Between May 2008 and June 2011, 48 patients were enrolled, 2 patients were not evaluable due to noncompliance to treatment and lost to follow up, 10 were still receiving treatment and therefore not evaluable. Thirty-six were evaluable, and were equally distributed between the real and sham acupuncture groups. Baseline characteristics were balanced between the two groups with regard to age, race, and body mass index (BMI) with the exception that baseline mean HAQ-DI was higher in the acupuncture group (0.9 vs 0.55, p=0.04). White/Black/Asian: 26/7/3, Median (range): age: 61 (45-82); BMI (kg/m2): 31.1 (22.9−59.6). At week 8, both groups showed a wide range of ΔHAQ-DI (ΔHAQ-DI =HAQ-DIweek8-HAQ-DIbaseline): from −1.38 to 0.5 in the acupuncture group versus from −1 to 0.12 in sham acupuncture group. There was no statistically significant difference in mean ΔHAQ-DI between the real and sham acupuncture groups (−0.33 vs −0.33, p=0.87). Eleven patients in each group (61%) reported decreased HAQ-DI scores, which correlated with improved function. There was no difference in mean ΔVAS between the real and sham acupuncture groups (−9.27 vs −13.82, p=0.67). No significant side effects were reported. Changes in other time points and in serum biomarkers will be presented at the meeting.
Conclusions: The majority of breast cancer patients experiencing AIMSS who participated in our study reported a reduced HAQ-DI score both from acupuncture and sham acupuncture. We did not observe significant differences between responses to real versus sham acupuncture after 8 weekly treatments. The study remains open to accrual to reach 50 evaluable patients.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-12-13.
Collapse
Affiliation(s)
- T Bao
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - K Tarpinian
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Medeiros
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - J Gould
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Jeter
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - L Cai
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - N Tait
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - J Shetty
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - J Lewis
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - L Gitten
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - K Betts
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Hoffman
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Feigenberg
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Chumsri
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - DK Armstronge
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Bardia
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Tan
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - J Stebbing
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - E Folkerd
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Dowsett
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - H Singh
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - K Tkaczuk
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - V Stearns
- 1University of Maryland Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hammersmith Hospitals NHS Trust Charing Cross Hospital, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
19
|
Mahmood U, Morris C, Neuner G, Koshy M, Kesmodel S, Buras R, Chumsri S, Bao T, Tkaczuk K, Feigenberg S. Equivalent Survival with Breast Conservation Therapy or Mastectomy in the Management of Young Women with Early-stage Breast Cancer. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Strongin A, Watts M, Ioffe O, Regine W, Tkaczuk K, Kesmodel S, Buras R, Feigenberg SJ. Abstract P4-11-18: CT Simulation Alone Appears To Be Appropriate for Pre-Operative Partial Breast Radiation. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p4-11-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Pre-operative radiotherapy is being evaluated at several centers as a method to potentially increase patient eligibility for partialbreast radiotherapy. Theoretically pre-operative radiotherapy will decrease the volume of normal tissue irradiated which could decrease the morbidity. This study was performed to determine whether CT based imaging could be used for radiotherapy planning.
Material and Methods: Between December 2008 and February 2010, 204 breast cancer patients were seen in the breast evaluation and treatment program clinic at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. Patients with a new diagnosis of breast cancer and no prior treatment were included in the study if they underwent MRI of the breast and a CT, including the breast, within 30 days of each other, and images were available for review. Measurements of maximum tumor dimension obtained from CT and MRI were compared. These measurements were also compared to the maximum pathologic tumor dimension, when pathology was available. Measurements were compared using correlative paired t-tests. Associations between these measurements and T stage, tumor diameter, nodal involvement, receptor status and histologic subtype were explored. Specifically, the risk of CT underestimating the size of the tumor in the pre-operative setting was also evaluated, with a 3 mm underestimation of size chosen as significant. Results: CT and MRI images were available for 40 patients. Twelve patients who underwent imaging after receiving induction chemotherapy were excluded, leaving 28 patients for analysis. In 25 patients, CT images were obtained as part of a staging PET/CT. Pathology was available in 19 patients; nine patients received neo-adjuvant chemotherapy after imaging was obtained. The average maximum tumor dimension was 10% smaller on CT than MRI (4.25 cm (range 1.1 — 9.1 cm) versus 4.72 cm (range 1.3 — 9.0 cm)), but this difference was not statistically significant. Tumor measurements obtained by CT and MRI were only statistically different in the presence of lobular carcinoma (p=0.049). The CT underestimated the MRI measurement by greater than 3 mm in 9 out of 28 (32.14%) patients, six of whom had extensive calcifications on mammogram. When the maximum tumor dimension obtained from CT was compared to pathological size, CT underestimated the pathologic tumor size by greater than 3 mm in only 4 out of 19 (21.1%) patients. All 4 patients had pathologic T3 tumors and were node positive. For comparison, the MRI similarly underestimated the tumor size in 3 of these 4 cases. Limiting our analysis to tumors less than 3 cm in diameter, only 1 out of 7 patients had a pathologic tumor size that was 3 mm greater than the maximum tumor dimension obtained from CT imaging.
Conclusions: Measurements of maximum tumor dimension on CT are on average 10% smaller than measurements obtained from MRI, although not statistically different. The risk of underestimating pathologic maximum tumor dimension was similar for CT and MRI. The risk appeared to be less for infiltrating ductal carcinoma and tumors < 3 cm. CT based treatment planning for pre-operative partial breast radiotherapy seems appropriate although additional data is needed to confirm these findings.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-11-18.
Collapse
Affiliation(s)
- A Strongin
- University of Maryland School of Medicine, Baltimore
| | - M Watts
- University of Maryland School of Medicine, Baltimore
| | - O Ioffe
- University of Maryland School of Medicine, Baltimore
| | - W Regine
- University of Maryland School of Medicine, Baltimore
| | - K Tkaczuk
- University of Maryland School of Medicine, Baltimore
| | - S Kesmodel
- University of Maryland School of Medicine, Baltimore
| | - R Buras
- University of Maryland School of Medicine, Baltimore
| | | |
Collapse
|
21
|
Weinstock C, Zhu Y, Bao T, Buras RR, Hanna NN, Tkaczuk K, Chumsri S. Abstract P6-06-01: Relationship between Vitamin D Deficiency and Breast Cancer Histology: A Retrospective Database Review. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-06-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Vitamin D deficiency has recently been shown to be correlated with high rates of developing breast cancer (Chen P et al, Breast Cancer Res Treat; Oct 2009). However, the association between the degree of vitamin D deficiency and specific histological subtypes of breast cancer remains unclear. Preclinical data has suggested that vitamin D plays an essential role in the terminal differentiation of breast cancer cells, and thus vitamin D deficiency would be associated with the pathogenesis of estrogen receptor negative tumors (Welsh J et al, Journal of Steroid Biochem Mol Biol; Feb 2003), in particular triple-negative tumors, which are associated with a particularly aggressive clinical course. Methods: Beginning in July 2008, the majority of newly diagnosed breast cancer patients at University of Maryland Greenebaum Cancer Center had Vitamin D 25-OH levels testedon initial presentation to the clinic. We conducted a retrospective chart review to obtain information about tumor histology and vitamin D levels in these patients. Results: We include data on 71 patients who presented with newly-diagnosed breast carcinoma or DCIS between June 2008 and December 2009. Average age at diagnosis was 57 (range 36-87), and 58% of patients were African American. Stage distribution of the cohort included; DCIS-3%, stage I-15%, stage II-41%, stage III-28%, and stage IV-10%. Overall, 80% of the patients were vitamin D deficient at diagnosis, with vitamin D levels under 30 ng/ml, and 57% had levels under 20 ng/ml. Patients with triple-negative tumors were the most likely to be vitamin D deficient at diagnosis (90%) compared to hormone receptor-positive patients (75%), and they had the lowest mean and median vitamin D levels compared to all other patients.
Percentage of patients with Vitamin D deficiency
Vitamin D level by histological subtype
Hormone receptor-positive patients were significantly more likely to have normal vitamin D levels at diagnosis and significantly less likely to have severe deficiency (level <10 ng/ml) than those with hormone receptor-negative tumors (p=0.037). African-American women in this cohort were also more likely to be severely vitamin D deficient, with levels <10 ng/ml, than were Caucasian women (34% vs. 7%, p=0.048). Conclusion: Vitamin D deficiency is common among patients with newly-diagnosed breast cancer. Patients with triple-negative tumors may have a higher likelihood of being vitamin D deficient than patients with other histological subtypes.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-06-01.
Collapse
Affiliation(s)
- C Weinstock
- University of Maryland Medical Center, Baltimore
| | - Y Zhu
- University of Maryland Medical Center, Baltimore
| | - T Bao
- University of Maryland Medical Center, Baltimore
| | - RR Buras
- University of Maryland Medical Center, Baltimore
| | - NN Hanna
- University of Maryland Medical Center, Baltimore
| | - K Tkaczuk
- University of Maryland Medical Center, Baltimore
| | - S. Chumsri
- University of Maryland Medical Center, Baltimore
| |
Collapse
|
22
|
Nichols EM, Feigenberg SJ, Marter K, Lasio G, Cheston SB, Tkaczuk K, Buras R, Kesmodel S, Regine WF. Abstract P4-11-11: Preoperative Radiotherapy Increases Eligibility for Partial Breast Irradiation by Significantly Reducing Normal Tissue Exposure. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p4-11-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: External-beam accelerated partial breast irradiation (EB-APBI) is the most common technique used on NSABP B-39 primarily due to the non-invasive nature of the treatment. Many patients thought to be eligible for EB-APBI become ineligible at the time of planning due to inability to meet dose-volumetric constraints. EB-APBI in the preoperative setting will reduce the volume of normal tissue treated potentially increasing the number of patients eligible for APBI. This study tested the hypothesis that pre-operative EB-APBI will not only decrease target volumes but will decrease normal tissue exposure significantly increasing eligibility for APBI.
Materials and Methods: Forty patients with 41 previously treated early stage breast cancers (tumors ≥4 cm) were retrospectively analyzed from a prospective cohort. Imaging studies (MRI, US and mammogram) were utilized to create a spherical pre-op tumor volume using the largest reported dimension centered within the previously contoured lumpectomy cavity (LPC). Plans were created and optimized for each patient using the pre-operative tumor volume (pre-op) and LPC (post-op) using NSABP B-39 guidelines. Dose-volumetric constraints were analyzed between the cohorts using a t-test analysis. The primary end-point was to evaluate for differences in patient eligibility and normal tissue exposure.
Results: The median tumor volume was 93 cc (range 24-570 cc) and 250 cc (range 46-879 cc) in the pre-and post-operative setting respectively. This reduction in tumor volume translated into an increase in patient eligibility for EB-APBI with 35/41 (85%) cases being eligible for EB-APBI in the preop setting versus 18/41 (44%) cases in the post-op setting (p=0.0002). In the pre-op setting 6 cases were ineligible due to violation of one constraint by 5% and no case violated multiple constraints. In the post-op setting, 12 cases had 1 and 11 cases multiple reasons for ineligibility due to exceeding dose constraints by 5%. The most common reason for ineligibility in both groups was > 60% of the ipsilateral breast volume receiving 50% of the dose. The mean volume of ipsilateral breast receiving 50% of the dose was 42% and 63% in the pre-and post-op groups respectively. The mean contralateral breast dose and ipsilateral lung V20 in the pre-and post-op groups were 1 versus 4% and 3 versus 9%. All DVH criteria were statistically significantly improved in the pre-op setting including heart V5 and V40, ipsilateral breast V5, V20, V50 and V80, contralateral breast dose, chest wall V5, V10 and V20; ipsilateral lung V5, V10, V20 and volume of skin receiving 50% of the dose. Contralateral lung dose and thyroid max dose were not significantly different between plans.
Conclusions: Administration of EB-APBI in the pre-op setting decreases the size of the target volume which significantly increases the utility of APBI nearly doubling the eligibility for APBI in this cohort. The largest benefit is seen by reducing the volume of breast receiving 50% of the dose. This decreased dose to normal tissues will potentially result in decreased morbidity and improved cosmesis.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-11-11.
Collapse
Affiliation(s)
| | | | - K Marter
- University of Maryland, Baltimore
| | - G Lasio
- University of Maryland, Baltimore
| | | | | | - R Buras
- University of Maryland, Baltimore
| | | | | |
Collapse
|
23
|
Serrero G, Serrero G, Tkaczuk K, Yue B, Kamimura S, Tait N, Zhan M, Ecklund D. GP88 Serum Level Is Increased in Breast Cancer Patients with Disease Progression. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
GP88 (progranulin) is an 88-kDa glycoprotein autocrine growth factor that plays a critical role in breast tumorigenesis. GP88 is expressed in human BC tumors in a positive correlation with their tumorigenicity. In estrogen receptor positive (ER+) cells, GP88 expression is low and is stimulated by estradiol whereas in ER negative (ER-) cells, it is constitutively overexpressed. In ER+ cells, increased GP88 expression was found to be associated with resistance to anti-estrogen therapy. In Her-2 overexpressing breast tumors, increased GP88 expression was associated with Herceptin resistance. Inhibition of GP88 expression in human breast adenocarcinoma cells resulted in a drastic reduction of tumor incidence and tumor growth in nude mice. Immunohistochemical studies carried out with 206 paraffin-embedded human breast biopsies have shown that GP88 is expressed in invasive ductal carcinomas in correlation with expression of markers of poor prognosis whereas normal tissues and benign breast lesions were negative. Importantly, high GP88 expression in tissue biopsies was accompanied by decreased disease-free and overall survival. Since GP88 contains a signal peptide for secretion, we have shown that GP88 can be found in serum. An IRB approve blood sampling study of 189 patients (Race: Caucasian- 91, African American-92, Asian-6; median age- 51 with a range from 26 to 81) established at the University of Maryland demonstrated that GP88 was measurable in serum and that GP88 serum level was statistically elevated in breast cancer patients when compared to healthy individuals. Median level of GP88 was 40.7 ng/ml (range 6.4-80) in early stage (stage 1 –3) BC pts (p- value = 0.007) and 45.3 ng/ml (range 9.8 to 158.4) in stage 4 metastatic BC patients (p-value= 0.0007). Statistically significant increase in circulating GP88 level was found in early stages as well as in metastatic disease when compared to healthy individuals.Since we have shown that GP88 tissue expression was associated with increased disease recurrence, the present study was focused on examining whether GP88 serum level was also increased in disease progression and could be used to monitor disease recurrence. Our data show that patients with disease recurrence or progression presented a 5 to 10 fold increase in their GP88 serum levels.This study identifies GP88 as a measurable biomarker for recurrence or disease progression not only at the tissue but also at the serum level.This study is supported by grants from MIPS, the Avon Foundation and from the National Cancer Institute.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6040.
Collapse
Affiliation(s)
| | - G. Serrero
- 2University of Maryland Greenebaum Cancer Center, MD,
| | - K. Tkaczuk
- 2University of Maryland Greenebaum Cancer Center, MD,
| | - B. Yue
- 1A&G Pharmaceutical Inc., MD,
| | | | - N. Tait
- 2University of Maryland Greenebaum Cancer Center, MD,
| | - M. Zhan
- 3University of Maryland School of Medicine, MD,
| | - D. Ecklund
- 4University of Maryland School of Pharmacy, MD,
| |
Collapse
|
24
|
Gardner L, Royak-Schaler R, Ryan A, Garrett-Ray S, Tkaczuk K, Zhan M, Nesbitt K, Kozlovsky A, Burroughs J, Green D. A Culturally-Specific Dietary Plan To Manage Weight Gain among African American Breast Cancer Survivors: A Feasibility Study. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-1053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. African American (AA) women are less likely to survive for five years after a breast cancer diagnosis than Caucasian women. The higher prevalence of obesity in AA women may contribute to this disparity. Weight gain following breast cancer treatment is one of the few modifiable risk factors for breast cancer recurrence and mortality. AA breast cancer survivors face unique cultural and economic barriers to adopting diets which reduce the likelihood of weight gain.Objective. To determine the feasibility of adopting and maintaining a culturally-specific low-fat eating plan in a population of low to middle income AA breast cancer survivors.Participants. AA women recruited through urban medical centers who were between 30 to 75 years old, had a confirmed diagnosis of stage 0, I, II, III, or IIIA primary breast cancer, and had incomes < $50,000 per year.Methods. A culturally-specific dietary intervention was developed, based on the Women's Intervention Nutrition Study (WINS), to reduce consumption of dietary fat to 25% of total calories, while increasing fruits and vegetables.Eligible participants were enrolled in a one-year feasibility study. Participants received the Culturally-Specific WINS Low-Fat Eating Plan (WLEP) and 8 individual nutritional counseling sessions with a trained diet technician, to help reduce and maintain their fat intake to 25% of total calories. The intervention also included bi-monthly educational group meetings and follow-up telephone contacts with diet technicians.Study Measures. Dietary patterns were assessed with 3-day food records at baseline and follow-up. Compliance with the Culturally-Specific WLEP was defined as 1) dietary fat intake ≤ 25% of total calories; and 2) at least 6 to 7 servings of fruits and vegetables per day. Psychosocial factors and dietary biomarkers were also measured at baseline and follow-up to examine their association with study outcomes. Psychosocial factors included perceived susceptibility to recurrence, quality of life, and social support. Dietary biomarkers included weight, height, waist-hip circumference, blood pressure, lipids, serum fatty acid concentrations, insulin and insulin-like growth factors, glucose, and levels of sex hormone-binding globulins.Results. A total of 9 AA breast cancer survivors are enrolled and receiving the intervention. Baseline and six-month follow-up results for the psychosocial factors and dietary biomarkers associated with dietary compliance and weight maintenance will be reported in October 2009.Conclusions. A population of low to middle income AA breast cancer survivors with limited education and resources demonstrated compliance with the Culturally-Specific WLEP, thereby reducing their risk of cancer recurrence through diet. Procedures and data from this feasibility study will be used in a multi-center clinical trial of the Culturally-Specific WLEP.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1053.
Collapse
Affiliation(s)
- L. Gardner
- 1University of Maryland School of Medicine, MD,
| | | | - A. Ryan
- 1University of Maryland School of Medicine, MD,
| | | | - K. Tkaczuk
- 1University of Maryland School of Medicine, MD,
| | - M. Zhan
- 1University of Maryland School of Medicine, MD,
| | - K. Nesbitt
- 1University of Maryland School of Medicine, MD,
| | | | | | - D. Green
- 1University of Maryland School of Medicine, MD,
| |
Collapse
|
25
|
Serrero G, Tkaczuk K, Zhan M, Tait N, Ilan C, Eklund D, Yue B. Association of serum levels of the growth factor GP88 with disease progression in breast cancer patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22021 Background: The autocrine growth factor GP88 is an important player in breast cancer. GP88 is expressed in human BC tumors in correlation with their tumorigenicity. Increased GP88 expression was associated with anti-estrogen therapy resistance in ER+ cells and Herceptin resistance in Her-2 overexpressing breast tumors. Inhibition of GP88 expression inhibited tumor incidence and growth in nude mice. Immunohistochemical studies have shown that GP88 is expressed in invasive ductal carcinomas (IDC) and that high GP88 expression correlated with increased recurrence and mortality. Since GP88 is found in serum, we hypothesized that GP88 was elevated in the sera of breast cancer patients compared to healthy individuals and that GP88 serum level increases with disease progression. Methods: An IRB approved prospective study was established at the University of Maryland Breast Clinic to determine the serum level of GP88 in breast cancer patients (BC pts). Approximately 5 ml of blood was drawn every three months. GP88 serum concentration was determined in triplicate by human GP88 enzyme immunoassay. 190 BC pts were accrued. Sera from healthy volunteers (HV) were obtained to establish GP88 baseline. BC patient characteristics: Caucasian- 91, African American-92, Asian-6; median age, 51 (range 29- 86), stage I - 48, II - 52, III - 26, IV - 63. Results: Median serum GP88 level was 28.7 ng/ml (range 16.6–38.2) in HV, 40.7 ng/ml (range 6.4–100) in early stage (stage 1 -3) BC pts (p- value = 0.007) and 45.3 ng/ml (range 9.8 to 158.4) in stage 4 BC patients (p- value= 0.0007). Statistically significant increase in serum GP88 level was found in early stages as well as in metastatic disease when compared to HV. In addition, patients that were initially diagnosed with early stage disease but recurred showed a 5 to 10 fold increase in their GP88 serum levels. Conclusions: GP88 serum level is significantly higher in the sera of BC than HV subjects. Moreover, GP88 serum level increased in association with disease recurrence and progression. This study identifies GP88 as a measurable biomarker for disease progression not only at the tissue but also at the serum level. These results are also interesting since GP88 is also a therapeutic target of malignant progression of breast carcinoma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Serrero
- A&G Pharmaceutical, Inc, Columbia,; University of Maryland, Baltimore,; University of Maryland, Baltimore
| | - K. Tkaczuk
- A&G Pharmaceutical, Inc, Columbia,; University of Maryland, Baltimore,; University of Maryland, Baltimore
| | - M. Zhan
- A&G Pharmaceutical, Inc, Columbia,; University of Maryland, Baltimore,; University of Maryland, Baltimore
| | - N. Tait
- A&G Pharmaceutical, Inc, Columbia,; University of Maryland, Baltimore,; University of Maryland, Baltimore
| | - C. Ilan
- A&G Pharmaceutical, Inc, Columbia,; University of Maryland, Baltimore,; University of Maryland, Baltimore
| | - D. Eklund
- A&G Pharmaceutical, Inc, Columbia,; University of Maryland, Baltimore,; University of Maryland, Baltimore
| | - B. Yue
- A&G Pharmaceutical, Inc, Columbia,; University of Maryland, Baltimore,; University of Maryland, Baltimore
| |
Collapse
|
26
|
Come SE, Parker LM, Wulf G, Kuter I, Ryan PD, Tkaczuk K, Borges V, Kasper H, Gelman R, Winer EP. Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1050] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1050 Background: At the approved dosage (AD) of 250 mg q 28d, fulvestrant has no dose-limiting toxicity and may not optimally inhibit/downregulate levels of ER. We evaluated the tolerability, efficacy, and pharmacokinetics of fulvestrant given at twice the AD. Methods: 35 postmenopausal patients with ER+ evaluable metastatic breast cancer who had not received endocrine therapy for advanced disease and were at least 12 months from the completion of any adjuvant endocrine therapy were enrolled in a single stage, phase II study. The median age was 64. 15 patients had received prior adjuvant endocrine treatment. 14 had visceral metastases. Treatment consisted of fulvestrant 500 mg (2 x 5 mL injections) on days 1, 15, 29, and q 28d thereafter. Toxicity and response were assessed q 28d by history, exam, and laboratory testing, and q 3 months by imaging. The primary endpoint was clinical benefit rate (CBR) defined as complete responses (CR) plus partial responses (PR) plus stable disease (SD) for > 6 months. This trial was powered to detect a 20% improvement in the 57% CBR reported for AD fulvestrant in the first-line metastatic setting (J Clin Oncol. 2004;22:1605–613). Results: Median time on study is 13 months (mo). 17 patients remain on treatment (8+ to 54+ mo). There has been no grade (gr) 3 or 4 treatment-related toxicity. Transient injection site discomfort or pruritis occurred in 13 patients (11 gr 1, 2 gr 2). A CBR of 86% was observed (95% CI 70%- 95%). The median time to progression is 22 mo. In the subset of 24 patients fulfilling RECIST criteria, 1 CR and 6 PR, and 15 SD were observed (overall response rate 29%, CBR 92%). Conclusions: Doubling the AD of fulvestrant does not increase toxicity. Monthly bilateral 5 mL injections are well tolerated. Importantly, the CBR is improved at this dose and schedule compared to the AD. [Table: see text]
Collapse
Affiliation(s)
- S. E. Come
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| | - L. M. Parker
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| | - G. Wulf
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| | - I. Kuter
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| | - P. D. Ryan
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| | - K. Tkaczuk
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| | - V. Borges
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| | - H. Kasper
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| | - R. Gelman
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| | - E. P. Winer
- Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Colorado Health Sciences Center, Denver, CO
| |
Collapse
|
27
|
Serrero G, Tkaczuk K, Zhan M, Tait N, Ilan C, Yue B. Elevated serum levels of the growth factor GP88 are found in breast cancer patients when compared to healthy individuals. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2006
Background: GP88 is an autocrine growth factor that plays a critical role in breast tumorigenesis. GP88 is expressed in human BC tumors in a positive correlation with their tumorigenicity. Increased GP88 expression is associated with resistance to anti-estrogen therapy in ER + cells and with herceptin resistance in Her-2 overexpressing breast tumors. Inhibition of GP88 expression in human breast adenocarcinoma inhibited tumor incidence and growth in nude mice. Immunohistochemical studies have shown that GP88 was expressed in invasive ductal carcinomas in correlation with the expression of poor prognosis markers whereas normal tissues and benign lesions were negative. High GP88 expression in tumor biopsies was accompanied by decreased disease-free survival. Since GP88 can be secreted, we have hypothesized that GP88 could be secreted in the circulation and found in serum. We examined whether GP88 could be found in the circulation and whether GP88 could be elevated in the sera of breast cancer patients when compared to healthy individuals.
 Methods: An IRB approved blood sampling study was conducted at the University of Maryland Breast Clinic to determine the serum level of GP88 in healthy volunteers (HV) and breast cancer patients (BC pts). Serum GP88 concentration was determined in triplicate by quantitative enzyme immunoassay. 189 BC pts were accrued. In addition, sera from 18 HV were obtained to establish a GP88 baseline in healthy volunteers. BC patient characteristics: Race: Caucasian- 91, African American-92, Asian-6; median age, 51 (range 29-86), stage I – 48, II - 52, III – 26, IV - 63.
 Results: Circulating GP88 was measurable in the serum. Median level of GP88 was 28.7 ng/ml (range 16.6-38.2) in HV; 40.7 ng/ml (range 6.4-100) in early stage (stage 1 –3) BC pts (p- value = 0.007) and 45.3 ng/ml (range 9.8 to 158.4) in stage 4 metastatic BC patients (p-value= 0.0007). Statistically significant increase in circulating GP88 level was found in early stages as well as in metastatic disease. Correlation studies with BC prognostic factors such as stage, tumor size, lymph node involvement, tumor grade and presence of ER and HER-2 will be presented.
 Conclusion: GP88 can be detected in the sera of HV and BC pts. Comparison between the two groups of subjects indicates that GP88 level is significantly higher in the sera of BC pts. These studies are important as they identify as a measurable circulating biomarker GP88 that is also a therapeutic target of malignant transformation or malignant progression of breast carcinoma (BC). Future studies will examine whether there is any correlation between the serum level of GP88 and therapeutic response to systemic therapy in breast cancer patients.
 This study was supported by grant from MIPS, the Avon Foundation and 1R43 CA 124179-01A1 from the National Institutes of Health.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2006.
Collapse
Affiliation(s)
- G Serrero
- 1 A&G Pharmaceutical Inc., Columbia, MD
- 2 Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - K Tkaczuk
- 2 Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - M Zhan
- 3 Epidemiology, University of Maryland Schol of Medicine, Baltimore, MD
| | - N Tait
- 2 Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - C Ilan
- 2 Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - B Yue
- 1 A&G Pharmaceutical Inc., Columbia, MD
| |
Collapse
|
28
|
Sylvester L, Laufman L, Jabboury K, Saleh M, Tkaczuk K, Volterra F, Arnott J, Hannah A, Sidor C, Miller K. Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11508 Background: MKC-1 (previously Ro 31–7453) is a novel cell cycle inhibitor with significant in vitro and in vivo activity against a wide range of tumor cell lines, including multi-drug resistant cell lines. Proteins identified as binding targets of MKC-1 include microtubules (colchicine binding site) and members of the importin-β family (proteins that play a critical role in nuclear transport and spindle formation). Objective responses (ORs) were observed in heavily pre-treated breast and NSCLC pts (Trigo Perez ASCO’03 A62; Kurup ASCO’03 A2725) treated at a dose of 95 mg/m2 BID given 14 days every 4 weeks with little toxicity. Salazar et al (2004 CCR 10:4374) recommended a higher oral dose (125 mg/m2 BID) on this schedule for further studies. This phase 2 trial is exploring the higher dose to maximize potential anticancer activity. Methods: Pts with MBC who had failed prior A and T and met eligibility criteria received MKC-1 at 125mg/m2 BID x 14d every 4 weeks. Pts with known treated and stable CNS metastases could enroll. Primary objective: OR by RECIST. Should 2 or more of the first 23 evaluable pts have an OR, enrollment will continue to 53 pts. Dose escalation/reductions are required based on toxicity (primarily neutropenia). Results: To date, a total of 20 pts have been enrolled (4 active in Cycles 1–5+). All female; median age/KPS of 60/90. 19% / 13% had received A / T in the neo/adjuvant setting; others had received A / T for metastatic disease. To date, a total of 48 cycles (median 2, range 1–8) were administered; of pts proceeding into Cycle 2, 40% and 20% had the dose increased or reduced, respectively. Severe drug-related toxicity (n=17) was observed in 3 pts (18%): ↑AST/ALT in 2 pts and parathesias in 1 pt. Drug related toxicity: nausea (47%), ↑ALT, diarrhea (both 24%), anemia, ↑AST, cough, fatigue, neutropenia and vomiting (all 18%). Two pts discontinued due to toxicity. One pt had complete resolution of measurable disease (1st observed after Cycle 4, confirmed after Cycle 6 with withdrawal for a new lesion at Cycle 8). An additional 2 pts had stable disease for 5 cycles (1 pt remains active). Conclusions: MKC-1 is well tolerated at the initial recommended dose for this schedule. Activity is observed in pts previously treated with A/T for MBC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Sylvester
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - L. Laufman
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - K. Jabboury
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - M. Saleh
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - K. Tkaczuk
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - F. Volterra
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - J. Arnott
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - A. Hannah
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - C. Sidor
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| | - K. Miller
- Orange Park Cancer Center, Orange Park, FL; Hematology Oncology Consultants, Inc., Columbus, OH; Jabboury Fndtn. for Cancer Research, Inc., Houston, TX; Georgia Cancer Specialists, Tucker, GA; University of Maryland, Baltimore, MD; Eastchester Center for Cancer Care, Bronx, NY; EntreMed Inc, Rockville, MD; Consultant, Sebastopol, CA; Indiana University Cancer Center, Indianapolis, IN
| |
Collapse
|
29
|
Serrero G, Tkaczuk K, Tait N, Golubeva O, Dai H, Feldman FS, Jones L. Circulating levels of the breast cancer growth factor GP88 in the serum of breast cancer (BC) patients. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.20050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20050 Background: The 88 kDa autocrine growth factor PC-Cell Derived Growth Factor (GP88) plays a critical role in breast tumorigenesis. GP88 expression was low in estrogen receptor positive cells, whereas in ER negative cells, it was constitutively overexpressed. Increased GP88 expression was associated with anti-estrogen therapy resistance in ER+ cells and Herceptin resistance in Her-2 overexpressing breast tumors. Antisense inhibition of GP88 expression in human breast adenocarcinoma lead to inhibition of tumor growth in vivo. Immunohistochemical studies have shown that GP88 was expressed in 80% of invasive ductal carcinomas in correlation with expression of poor prognosis markers whereas normal tissues and benign breast lesions were negative. Since GP88 is secreted by breast cancer cells, we examined whether GP88 was found in the circulation at an elevated level in the sera of breast cancer patients when compared to healthy individuals. Methods: A blood sampling study was conducted to determine the serum level of GP88 in healthy volunteers (HV) and breast cancer patients (BC pts). Ten ml of blood was drawn every three months to obtain serum. GP88 serum concentration was determined in triplicate by quantitative enzyme immunoassay using human GP88 as standard. 126 BC pts were accrued. . In addition, sera from 53 healthy volunteers were obtained to establish a GP88 baseline in HV. BC pts characteristics: race: Caucasian- 61, African American-60, Asian-5; median age: 52.5 (range 26–84), stage I-32, II-34, III-18, IV-42. Results: Circulating GP88 was measurable in the serum. Median level of GP88 was 32.8 ng/ml (range 15.3–42.8) in HV and 43.8 ng/ml (range 15.4–158.4) in BC pts, (p-value = 0.0007). Conclusions: GP88 is measurable in the sera of HV and BC pts. Comparison between the two groups indicates that GP88 level is significantly higher in the sera of BC pts. These studies are important since it identifies GP88 as a measurable biomarker that is also a therapeutic target of malignant transformation or malignant progression of breast carcinoma (BC). Future studies will examine the correlation of GP88 level with BC prognostic factors. Correlation between the serum level of GP88 and therapeutic response to systemic therapy in breast cancer patients will also be assessed. [Table: see text]
Collapse
Affiliation(s)
- G. Serrero
- A&G Pharmaceutical Inc, Columbia, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - K. Tkaczuk
- A&G Pharmaceutical Inc, Columbia, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - N. Tait
- A&G Pharmaceutical Inc, Columbia, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - O. Golubeva
- A&G Pharmaceutical Inc, Columbia, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - H. Dai
- A&G Pharmaceutical Inc, Columbia, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - F. S. Feldman
- A&G Pharmaceutical Inc, Columbia, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD
| | - L. Jones
- A&G Pharmaceutical Inc, Columbia, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD
| |
Collapse
|
30
|
Gutt R, Yovino S, Chin L, Regine W, Amin P, Tkaczuk K, Kwok Y. Gamma Knife stereotactic radiosurgery in the treatment of brain metastases from breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10555 Background: Outcomes of gamma knife stereotactic radiosurgery (GK-SRS) for patients with brain metastases specifically from breast cancer have not been well-defined. This study was undertaken to report the long-term experience with GK-SRS in this subset of patients. Methods: From 1995 to 2005, 75 patients with 162 brain lesions were treated with GK-SRS at the University of Maryland Medical Center. Complete follow-up data were available in 65 patients. Additional whole brain radiation therapy (WBRT) was administered to 53 (81.5%) patients. The median WBRT dose was 36.75 Gy (30.0–45.0 Gy). The median number of lesions treated with GK-SRS was 2 (1–8 lesions). The median follow-up, age, and KPS were 7.2 months (0.4–75.7 months), 53.5 years (23–81 years), and 90 (40–100), respectively. The factors included in the univariate and multivariate analyses for overall survival (OS) and progression free survival (PFS) were age, Karnofsky Performance Status (KPS), tumor histology, estrogen receptor status, Her-2-neu status, number of intracranial lesions, and presence of systemic disease. Results: Median PFS and OS from GK-SRS were 5.3 months (0.4–33.2 months) and 8.1 months (0.4–75.7 months), respectively. The 6, 12, and 24 month actuarial PFS were 47.8%, 24.9%, and 9.6% respectively. The 6, 12, and 24 month actuarial OS were 60.7%, 39.1%, and 18.1% respectively. The tumor local control after WBRT and GK-SRS was 87.7%. Radiation necrosis was a complication in 10.8% of patients. Forty-seven (72.3%) patients had neurological symptoms prior to gamma knife treatment. Seven (14.9%) and 9 (19.1%) of these patients experienced symptom resolution and significant symptomatic improvement, respectively. Multivariate and univariate analysis did not reveal any of the prognostic factors in question to be significantly associated with OS nor PFS. Conclusions: This relatively large cohort of patients experienced poor survival outcomes despite aggressive therapy with WBRT and GK-SRS. However, GK-SRS can provide significant symptomatic relief, with acceptable complication rates. More research is required to improve the survival of breast cancer patients with intracranial metastases. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Gutt
- University of Maryland School of Medicine, Baltimore, MD
| | - S. Yovino
- University of Maryland School of Medicine, Baltimore, MD
| | - L. Chin
- University of Maryland School of Medicine, Baltimore, MD
| | - W. Regine
- University of Maryland School of Medicine, Baltimore, MD
| | - P. Amin
- University of Maryland School of Medicine, Baltimore, MD
| | - K. Tkaczuk
- University of Maryland School of Medicine, Baltimore, MD
| | - Y. Kwok
- University of Maryland School of Medicine, Baltimore, MD
| |
Collapse
|
31
|
Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444-54. [PMID: 11230490 DOI: 10.1200/jco.2001.19.5.1444] [Citation(s) in RCA: 446] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC). PATIENTS AND METHODS Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity. Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF). Antitumor efficacy was assessed by objective tumor response rates (World Health Organization criteria), time to progression, and survival. RESULTS Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002). Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04). MC patients also experienced less grade 4 neutropenia. Antitumor efficacy of MC versus AC was comparable: objective response rates, 43% versus 43%; median time to progression, 5.1% versus 5.5 months; median time to treatment failure, 4.6 versus 4.4 months; and median survival, 19 versus 16 months. CONCLUSION Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
Collapse
Affiliation(s)
- G Batist
- Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Nemunaitis J, Eager R, Twaddell T, Corey A, Sekar K, Tkaczuk K, Thompson J, Hoff PM, Pazdur R. Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. J Clin Oncol 2000; 18:3423-34. [PMID: 11013283 DOI: 10.1200/jco.2000.18.19.3423] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of emitefur (BOF-A2) in patients with advanced solid tumors. METHODS This was a phase I dose-escalating trial in which cohorts of patients received BOF-A2 (cohort 1, 300 mg/m(2) orally [PO] tid; cohort 2, 200 mg/m(2) PO tid; cohort 3, 200 mg/m(2) bid; and cohort 4, 250 mg/m(2) bid) for 14 consecutive days followed by 1 week of rest (cycle 1). Pharmacokinetics, toxicity, and tumor response were monitored. RESULTS Nineteen patients received 110 cycles (three patients in cohort 1, three patients in cohort 2, 10 patients in cohort 3, and three patients in cohort 4). DLT (grade 3 stomatitis, diarrhea, leukopenia) was observed in cohorts 1, 2, and 4. Pharmacokinetics indicated that prolonged systemic expression of fluorouracil (5-FU) is maintained after administration of BOF-A2 at a dose of 200 mg bid for 14 days. The mean steady-state concentration of plasma 5-FU was > or = 24 ng/mL, which was 184-fold greater than the minimum effective cytotoxic concentration in vitro. Lack of variation of 5-FU trough levels within a day at steady-state indicates suppression of circadian variation. One patient in cohort 3 achieved a partial response and five patients maintained stable disease in excess of 6 months. CONCLUSION BOF-A2 at a dose of 200 mg PO bid for 14 days followed by 7 days of rest is well tolerated. Prolonged exposure to 5-FU above the predicted preclinical minimum effective concentration is maintained, without evidence of circadian variation. Furthermore, evidence of antitumor activity is suggested.
Collapse
|
33
|
Abstract
BACKGROUND Tamoxifen-treated breast carcinoma survivors are at elevated risk of endometrial carcinoma. Whether to recommend annual surveillance for uterine abnormalities in this population is currently under debate. METHODS This study was a cross-sectional, community-based investigation of tamoxifen use and the frequency of surveillance for endometrial carcinomas in 541 women with breast carcinoma. Study participants whose breast carcinoma was diagnosed in 1994 were interviewed in 1998. Data were collected from a telephone interview and from a cancer registry record. Tests for uterine abnormalities, based on participant reports of endometrial biopsy and transvaginal ultrasound, were categorized according to frequency. Testing for uterine abnormalities was defined as irregular if women reported tests once every 3 years, on average, and as regular, if they reported annual tests. RESULTS Forty-nine percent of respondents were current tamoxifen users, 12% were former tamoxifen users, and 39% reported never taking tamoxifen. Of respondents with a uterus (n = 385), 19% reported irregular and 30% regular testing for uterine abnormalities after their breast carcinoma diagnosis. Respondents more frequently reported transvaginal ultrasound (37%) than endometrial biopsy (29%). Women 65 years of age and older were significantly less likely to report regular surveillance for uterine abnormalities (16%) than those younger than 65 years (35%). Current tamoxifen users more frequently reported regular surveillance (43%) than either former (35%) or never tamoxifen users (15%). Multivariable analyses showed tamoxifen users were more likely to have regular (odds ratio [OR], 9.8; 95% confidence interval [CI], 4.4-21.8) or to have irregular testing for uterine abnormalities (OR, 3.9; 95% CI, 1.9-8.1) compared with women who never used tamoxifen, after adjustment for age, number of recent gynecologic visits, and gynecologic symptoms. CONCLUSIONS The results of the current study indicate that half of the breast carcinoma survivors in this population were tested for uterine abnormalities. Although at increased risk, 38% of tamoxifen users never had a test. Clear guidelines need to be established for the type and frequency of testing for uterine abnormalities among tamoxifen-treated breast carcinoma patients.
Collapse
Affiliation(s)
- M D Althuis
- Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Toppmeyer D, Seidman A, Overmoyer B, Pollak M, Verma S, Russell C, Tkaczuk K, Del Prete S, Schwartz G, Harding M. A Phase II study of IncelTM (biricodar, VX-710) in combination with paclitaxel in women with advanced breast cancer refractory to paclitaxel. Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81708-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|